{"id":"intravenous-omeprazole-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Hypomagnesemia (with chronic use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Omeprazole binds to and inactivates the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. This results in sustained reduction of both basal and stimulated gastric acid secretion. The intravenous formulation allows for rapid onset and is used in acute settings where oral administration is not feasible.","oneSentence":"Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:52.294Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute gastric acid suppression in patients unable to take oral medication"},{"name":"Prevention and treatment of stress-related mucosal damage"},{"name":"Management of gastroesophageal reflux disease (GERD) in acute settings"}]},"trialDetails":[{"nctId":"NCT05582174","phase":"PHASE4","title":"PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-18","conditions":"Upper GI Bleeding, Proton Pump Inhibitors","enrollment":594},{"nctId":"NCT03358706","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-02","conditions":"Crohn Disease, Ulcerative Colitis","enrollment":28},{"nctId":"NCT05487235","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2022-08-17","conditions":"Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":57},{"nctId":"NCT00001337","phase":"PHASE2","title":"Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1993-05-08","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma","enrollment":348},{"nctId":"NCT06561542","phase":"PHASE1","title":"A Phase I Study of LX22001 for Injection in Healthy Subjects","status":"RECRUITING","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2024-08-05","conditions":"Healthy","enrollment":70},{"nctId":"NCT04254783","phase":"PHASE1","title":"A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-05-27","conditions":"Ulcerative Colitis (UC), Crohn's Disease","enrollment":20},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT03452865","phase":"PHASE3","title":"Esomeprazole to Reduce Organ Failure in Sepsis","status":"COMPLETED","sponsor":"Università Vita-Salute San Raffaele","startDate":"2020-01-28","conditions":"Sepsis, Septic Shock","enrollment":300},{"nctId":"NCT05624229","phase":"PHASE4","title":"Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2023-10-01","conditions":"Upper Gastrointestinal Hemorrhage","enrollment":672},{"nctId":"NCT02197039","phase":"","title":"The Selection Criteria for the Second-look Endoscopy Among Patients With Bleeding Peptic Ulcers","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2011-08","conditions":"Peptic Ulcer Hemorrhage","enrollment":316},{"nctId":"NCT02760615","phase":"PHASE4","title":"Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2016-11-01","conditions":"Colitis, Ulcerative, Crohn Disease","enrollment":""},{"nctId":"NCT01579539","phase":"PHASE3","title":"The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2013-06-27","conditions":"Thyroid-associated Ophthalmopathy, Dry Eye Syndrome","enrollment":18},{"nctId":"NCT01123031","phase":"PHASE4","title":"Oral vs Intravenous and Proton Pump Inhibitor (PPI）for Peptic Ulcer Bleeding (PUB)","status":"WITHDRAWN","sponsor":"Changhua Christian Hospital","startDate":"2010-04","conditions":"Upper Gastrointestinal Bleeding","enrollment":""},{"nctId":"NCT04170270","phase":"EARLY_PHASE1","title":"Oral Omeprazole in Bleeding Peptic Ulcer","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-11","conditions":"Bleeding Peptic Ulcer","enrollment":100},{"nctId":"NCT01822600","phase":"PHASE4","title":"The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2010-01","conditions":"Peptic Ulcer Bleeding, Hypoalbuminemia","enrollment":91},{"nctId":"NCT03388463","phase":"NA","title":"Single Dose Omeprazole Versus High Dose in High-risk Critically Ill Patients.","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2016-05-11","conditions":"Critical Illness","enrollment":110},{"nctId":"NCT03362281","phase":"PHASE3","title":"Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2014-10","conditions":"Peptic Ulcer Hemorrhage","enrollment":540},{"nctId":"NCT03362268","phase":"PHASE2","title":"IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2014-02","conditions":"Peptic Ulcer Hemorrhage","enrollment":180},{"nctId":"NCT02479581","phase":"PHASE2","title":"The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Xiangya Hospital of Central South University","startDate":"2015-07","conditions":"Valvular Heart Disease","enrollment":226},{"nctId":"NCT02157376","phase":"PHASE3","title":"Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-07","conditions":"Stress Ulcer Prophylaxis","enrollment":343},{"nctId":"NCT00519519","phase":"PHASE3","title":"Optimal Dose of Omeprazole After Endoscopic Treatment of Bleeding Peptic Ulcers","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2004-07","conditions":"Bleeding Peptic Ulcers Disease","enrollment":126},{"nctId":"NCT02205489","phase":"PHASE4","title":"Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2014-10","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":58},{"nctId":"NCT02536989","phase":"PHASE4","title":"Different Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent Clot","status":"COMPLETED","sponsor":"Far Eastern Memorial Hospital","startDate":"2009-03","conditions":"Peptic Ulcer, Hemorrhage","enrollment":40},{"nctId":"NCT02593448","phase":"PHASE4","title":"Influence of Cardiopulmonary Bypass, and Sevoflurane or Propofol Anesthesia, on Tissue Oxygen Saturation.","status":"COMPLETED","sponsor":"Medical University of Gdansk","startDate":"2012-03","conditions":"NIR Spectroscopy","enrollment":64},{"nctId":"NCT01591083","phase":"PHASE4","title":"The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2011-08","conditions":"Peptic Ulcer Bleeding","enrollment":474},{"nctId":"NCT02307591","phase":"PHASE2, PHASE3","title":"Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)","status":"WITHDRAWN","sponsor":"Emergency NGO Onlus","startDate":"2014-12","conditions":"Ebola Virus Disease","enrollment":""},{"nctId":"NCT01142245","phase":"PHASE3","title":"Effect of IV and Oral Esomeprazole in Prevention of Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2008-01","conditions":"Peptic Ulcer, Bleeding","enrollment":263},{"nctId":"NCT02444507","phase":"PHASE4","title":"A Pharmacokinetic Study to Evaluate the Bioequivalence of a Test Formulation Compared to an Equivalent Dose of a Reference Drug Product","status":"UNKNOWN","sponsor":"isRed Pharma & Biotech Research Corporation","startDate":"2015-04","conditions":"Healthy Adult Subjects","enrollment":14},{"nctId":"NCT00881413","phase":"PHASE4","title":"Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding","status":"WITHDRAWN","sponsor":"Lotung Poh-Ai Hospital","startDate":"","conditions":"Peptic Ulcer","enrollment":""},{"nctId":"NCT00247130","phase":"PHASE4","title":"Comparison of Intravenous Omeprazole to Ranitidine on Recurrent Bleeding After Endoscopic Treatment of Bleeding Ulcer","status":"WITHDRAWN","sponsor":"Keio University","startDate":"2005-10","conditions":"Peptic Ulcers","enrollment":""},{"nctId":"NCT02197143","phase":"PHASE4","title":"A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain","status":"COMPLETED","sponsor":"Pamukkale University","startDate":"2013-03","conditions":"Dyspepsia","enrollment":286},{"nctId":"NCT00164788","phase":"PHASE2","title":"A Comparison of Gastric pH Control With High Dose Intravenous or Oral Esomeprazole","status":"TERMINATED","sponsor":"Chinese University of Hong Kong","startDate":"2004-07","conditions":"Gastrointestinal Hemorrhage","enrollment":7},{"nctId":"NCT00164931","phase":"PHASE3","title":"A Study Comparing High Dose Omeprazole Infusion Against Scheduled Second Endoscopy for Bleeding Peptic Ulcer","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2003-10","conditions":"Peptic Ulcer Hemorrhage","enrollment":240},{"nctId":"NCT00629564","phase":"PHASE4","title":"An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-09","conditions":"GERD","enrollment":60},{"nctId":"NCT00635414","phase":"PHASE4","title":"Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-08","conditions":"GERD","enrollment":60},{"nctId":"NCT00625495","phase":"PHASE4","title":"Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-09","conditions":"Gastroesophageal Reflux Disease","enrollment":60},{"nctId":"NCT00206050","phase":"PHASE4","title":"Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Healthy","enrollment":40},{"nctId":"NCT00838682","phase":"PHASE4","title":"Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers","status":"TERMINATED","sponsor":"The Catholic University of Korea","startDate":"2006-04","conditions":"Peptic Ulcer Hemorrhage","enrollment":106}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intravenous omeprazole infusion","genericName":"Intravenous omeprazole infusion","companyName":"Chinese University of Hong Kong","companyId":"chinese-university-of-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells. Used for Acute gastric acid suppression in patients unable to take oral medication, Prevention and treatment of stress-related mucosal damage, Management of gastroesophageal reflux disease (GERD) in acute settings.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}